Literature DB >> 23133818

The role of PET/CT in decreasing inter-observer variability in treatment planning and evaluation of response for cervical cancer.

Ajay Tejwani1, Amir Lavaf, Kapila Parikh, Bahaa Mokhtar, Uma Swamy, Joana Emmolo, Adel Guirguis, Hani Ashamalla.   

Abstract

We have previously introduced anatomic biologic contouring (ABC) with PET/CT, using a distinct "halo" to unify contouring methods in treatment planning for lung and head and neck cancers. The objective of this study is to assess the utility of PET/CT in planning and treatment response for cervical cancer. Forty-two patients with stages II-IIIB cervix cancer were planned for irradiation using PET/CT. A CT-based Gross Tumor Volume (GTV-CT) was delineated by two independent observers while the PET remained obscured. The Planning Target Volume (PTV) was obtained by adding a 1.5 cm margin around the GTV. The same volumes were recontoured using PET/CT data and termed GTV-ABC and PTV-ABC, respectively. The values of GTV-CT and GTV-ABC and the absolute differences between the two observers were analyzed. Additionally, 23 of these patients had PET/CT performed 3 months after treatment. The anatomic biologic value (ABV) was calculated using the product of maximum diameter and mean SUV of the cervical tumor. The pre- and post-treatment ABVs were compared. A "halo" was observed around areas of maximal SUV uptake. The mean halo SUV was 1.91 ± 0.56 (SD). The mean halo thickness was 2.12 ± 0.5 (SD) mm. Inter-observer GTV variability decreased from a mean volume difference of 55.36 cm(3) in CT-based planning to 12.29 cm(3) in PET/CT-based planning with a respective decrease in standard deviation (SD) from 55.78 to 10.24 (p <0.001). Comparison of mean pre-treatment and post-treatment ABV's revealed a decrease of ABV from 48.2 to 7.8 (p<0.001). PET/CT is a valuable tool in radiation therapy planning and evaluation of treatment response for cervical cancer. A clearly visualized "halo" was successfully implemented in GTV contouring in cervical cancer, resulting in decreased inter-observer variability in planning. PET/CT has the ability to quantify treatment response using anatomic biologic value.

Entities:  

Keywords:  Cervical cancer; PET/CT; inter-observer variability; positron emission tomography; treatment planning

Year:  2012        PMID: 23133818      PMCID: PMC3477735     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  20 in total

1.  18F-deoxyglucose positron emission tomography (FDG-PET) for the planning of radiotherapy in lung cancer: high impact in patients with atelectasis.

Authors:  U Nestle; K Walter; S Schmidt; N Licht; C Nieder; B Motaref; D Hellwig; M Niewald; D Ukena; C M Kirsch; G W Sybrecht; K Schnabel
Journal:  Int J Radiat Oncol Biol Phys       Date:  1999-06-01       Impact factor: 7.038

2.  FDG-PET in radiotherapy treatment planning: Pandora's box?

Authors:  Arnold C Paulino; Peter A S Johnstone
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-05-01       Impact factor: 7.038

3.  The role of PET/CT in the management of patients with cervical cancer: practice patterns of the members of the Society of Gynecologic Oncologists.

Authors:  Nora T Kizer; Israel Zighelboim; Ashley S Case; Summer B Dewdney; Premal H Thaker; L Stewart Massad
Journal:  Gynecol Oncol       Date:  2009-05-14       Impact factor: 5.482

4.  Clinical outcomes of definitive intensity-modulated radiation therapy with fluorodeoxyglucose-positron emission tomography simulation in patients with locally advanced cervical cancer.

Authors:  Elizabeth A Kidd; Barry A Siegel; Farrokh Dehdashti; Janet S Rader; Sasa Mutic; David G Mutch; Matthew A Powell; Perry W Grigsby
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-10-31       Impact factor: 7.038

Review 5.  Expanding role of positron emission tomography in cancer of the uterine cervix.

Authors:  Joseph G Rajendran; Benjamin E Greer
Journal:  J Natl Compr Canc Netw       Date:  2006-05       Impact factor: 11.908

Review 6.  Positron emission tomography in gynecological malignancies.

Authors:  Rakesh Kumar; Anil Chauhan; Suman Jana; Simin Dadparvar
Journal:  Expert Rev Anticancer Ther       Date:  2006-07       Impact factor: 4.512

7.  The contribution of integrated PET/CT to the evolving definition of treatment volumes in radiation treatment planning in lung cancer.

Authors:  Hani Ashamalla; Sameer Rafla; Kapila Parikh; Bahaa Mokhtar; Ganesh Goswami; Shravan Kambam; Hussain Abdel-Dayem; Adel Guirguis; Pamela Ross; Alex Evola
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-24       Impact factor: 7.038

8.  The impact of (18)FDG-PET on target and critical organs in CT-based treatment planning of patients with poorly defined non-small-cell lung carcinoma: a prospective study.

Authors:  Katherine Mah; Curtis B Caldwell; Yee C Ung; Cyril E Danjoux; Judith M Balogh; S Nimu Ganguli; Lisa E Ehrlich; Romeo Tirona
Journal:  Int J Radiat Oncol Biol Phys       Date:  2002-02-01       Impact factor: 7.038

9.  Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy in postoperative treatment of endometrial and cervical cancer.

Authors:  William Small; Loren K Mell; Penny Anderson; Carien Creutzberg; Jennifer De Los Santos; David Gaffney; Anuja Jhingran; Lorraine Portelance; Tracey Schefter; Revathy Iyer; Mahesh Varia; Kathryn Winter; Arno J Mundt
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-26       Impact factor: 7.038

10.  FDG-PET in cervical cancer: staging, re-staging and follow-up.

Authors:  Maria Bjurberg; Elisabeth Kjellén; Tomas Ohlsson; Mona Ridderheim; Eva Brun
Journal:  Acta Obstet Gynecol Scand       Date:  2007-09-04       Impact factor: 3.636

View more
  9 in total

1.  Overcoming the hurdles of using PET/CT for target volume delineation in curative intent radiotherapy of non-small cell lung cancer.

Authors:  Leila Tchelebi; Hani Ashamalla
Journal:  Ann Transl Med       Date:  2015-08

Review 2.  Quantum dot-based nanoprobes for in vivo targeted imaging.

Authors:  Y Zhu; H Hong; Z P Xu; Z Li; W Cai
Journal:  Curr Mol Med       Date:  2013-12       Impact factor: 2.222

Review 3.  Multimodality imaging of RNA interference.

Authors:  T R Nayak; L K Krasteva; W Cai
Journal:  Curr Med Chem       Date:  2013       Impact factor: 4.530

Review 4.  Current Development of Nano-Drug Delivery to Target Macrophages.

Authors:  Donglin Cai; Wendong Gao; Zhelun Li; Yufeng Zhang; Lan Xiao; Yin Xiao
Journal:  Biomedicines       Date:  2022-05-23

5.  Comparison of rigid and deformable image registration for nasopharyngeal carcinoma radiotherapy planning with diagnostic position PET/CT.

Authors:  Yudai Kai; Hidetaka Arimura; Ryo Toya; Tetsuo Saito; Tomohiko Matsuyama; Yoshiyuki Fukugawa; Shinya Shiraishi; Yoshinobu Shimohigashi; Masato Maruyama; Natsuo Oya
Journal:  Jpn J Radiol       Date:  2019-12-13       Impact factor: 2.374

6.  Application of FDG-PET/CT in Radiation Oncology.

Authors:  Jun Li; Ying Xiao
Journal:  Front Oncol       Date:  2013-04-11       Impact factor: 6.244

7.  Determination of an optimal standardized uptake value of fluorodeoxyglucose for positron emission tomography imaging to assess pathological volumes of cervical cancer: a prospective study.

Authors:  Ying Zhang; Jing Hu; Hong-Jun Lu; Jian-Ping Li; Ning Wang; Wei-Wei Li; Yong-Chun Zhou; Jun-Yue Liu; Sheng-Jun Wang; Jing Wang; Xia Li; Wan-Ling Ma; Li-Chun Wei; Mei Shi
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

8.  The Anatomical Biological Value on Pretreatment (18)F-fluorodeoxyglucose Positron Emission Tomography Computed Tomography Predicts Response and Survival in Locally Advanced Head and Neck Cancer.

Authors:  Hani Ashamalla; Malcolm Mattes; Adel Guirguis; Arifa Zaidi; Bahaa Mokhtar; Ajay Tejwani
Journal:  World J Nucl Med       Date:  2014-05

9.  Appropriate magnetic resonance imaging techniques for gross tumor volume delineation in external beam radiation therapy of locally advanced cervical cancer.

Authors:  Yingqiu Song; Beth Erickson; Xiaojian Chen; Guiling Li; Gang Wu; Eric Paulson; Paul Knechtges; X Allen Li
Journal:  Oncotarget       Date:  2018-01-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.